Choroidal Melanoma

Oncology
2
Pipeline Programs
2
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Aura Biosciences
Aura BiosciencesMA - Boston
3 programs
1
Bel-sarPhase 31 trial
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal MelanomaN/A1 trial
Non-interventional, digital, patient-reported, real-world studyN/A1 trial
Active Trials
NCT03941379RecruitingEst. Dec 2029
NCT07421739RecruitingEst. Aug 2028
NCT06007690RecruitingEst. Aug 2028
Genentech
GenentechCA - Oceanside
1 program
1
ranibizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00765921Completed40Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Aura BiosciencesBel-sar
Genentechranibizumab
Aura BiosciencesNon-interventional, digital, patient-reported, real-world study
Aura BiosciencesA Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Clinical Trials (4)

Total enrollment: 40 patients across 4 trials

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Start: Dec 2023Est. completion: Aug 2028
Phase 3Recruiting

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Start: Jun 2008Est. completion: Sep 201640 patients
Phase 1Completed
NCT07421739Aura BiosciencesNon-interventional, digital, patient-reported, real-world study

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Start: Nov 2025Est. completion: Aug 2028
N/ARecruiting
NCT03941379Aura BiosciencesA Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Start: Mar 2019Est. completion: Dec 2029
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 40 patients
2 companies competing in this space